nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—CHEK2—ovarian cancer	0.289	0.657	CbGaD
Bosutinib—EGFR—ovarian cancer	0.115	0.263	CbGaD
Bosutinib—EGFR—Docetaxel—ovarian cancer	0.044	0.571	CbGbCtD
Bosutinib—ABCB1—ovarian cancer	0.0351	0.0799	CbGaD
Bosutinib—ABCB1—Topotecan—ovarian cancer	0.00732	0.095	CbGbCtD
Bosutinib—ABCB1—Vinorelbine—ovarian cancer	0.00516	0.0669	CbGbCtD
Bosutinib—CYP3A4—Topotecan—ovarian cancer	0.00439	0.0569	CbGbCtD
Bosutinib—ABCB1—Paclitaxel—ovarian cancer	0.00362	0.047	CbGbCtD
Bosutinib—CYP3A4—Vinorelbine—ovarian cancer	0.00309	0.0401	CbGbCtD
Bosutinib—ABCB1—Docetaxel—ovarian cancer	0.00262	0.034	CbGbCtD
Bosutinib—CYP3A4—Paclitaxel—ovarian cancer	0.00217	0.0282	CbGbCtD
Bosutinib—ABCB1—Doxorubicin—ovarian cancer	0.00195	0.0253	CbGbCtD
Bosutinib—CYP3A4—Docetaxel—ovarian cancer	0.00157	0.0204	CbGbCtD
Bosutinib—Gefitinib—CHEK2—ovarian cancer	0.00155	0.41	CrCbGaD
Bosutinib—CYP3A4—Doxorubicin—ovarian cancer	0.00117	0.0152	CbGbCtD
Bosutinib—Vandetanib—VEGFA—ovarian cancer	0.000772	0.204	CrCbGaD
Bosutinib—ROCK1—Irinotecan—Topotecan—ovarian cancer	0.000659	0.144	CbGdCrCtD
Bosutinib—Vandetanib—EGFR—ovarian cancer	0.000651	0.172	CrCbGaD
Bosutinib—Gefitinib—EGFR—ovarian cancer	0.000619	0.164	CrCbGaD
Bosutinib—MAP4K4—Irinotecan—Topotecan—ovarian cancer	0.000588	0.129	CbGdCrCtD
Bosutinib—EPHB2—Irinotecan—Topotecan—ovarian cancer	0.0005	0.109	CbGdCrCtD
Bosutinib—WEE1—Paclitaxel—Docetaxel—ovarian cancer	0.000384	0.0842	CbGdCrCtD
Bosutinib—CASK—Irinotecan—Topotecan—ovarian cancer	0.000379	0.083	CbGdCrCtD
Bosutinib—CDK2—Paclitaxel—Docetaxel—ovarian cancer	0.000313	0.0687	CbGdCrCtD
Bosutinib—PTK2—Irinotecan—Topotecan—ovarian cancer	0.000303	0.0663	CbGdCrCtD
Bosutinib—CHEK2—Docetaxel—Paclitaxel—ovarian cancer	0.000193	0.0422	CbGdCrCtD
Bosutinib—Gefitinib—ABCB1—ovarian cancer	0.000188	0.0498	CrCbGaD
Bosutinib—CDK2—Vinblastine—Vinorelbine—ovarian cancer	0.000173	0.038	CbGdCrCtD
Bosutinib—IRAK1—female reproductive system—ovarian cancer	0.00014	0.000954	CbGeAlD
Bosutinib—DMPK—lymph node—ovarian cancer	0.00014	0.000951	CbGeAlD
Bosutinib—WEE1—lymph node—ovarian cancer	0.00014	0.000951	CbGeAlD
Bosutinib—MAP4K4—testis—ovarian cancer	0.00014	0.00095	CbGeAlD
Bosutinib—MAP4K5—gonad—ovarian cancer	0.000139	0.000949	CbGeAlD
Bosutinib—MAP3K3—gonad—ovarian cancer	0.000139	0.000949	CbGeAlD
Bosutinib—CSNK1E—female gonad—ovarian cancer	0.000139	0.000946	CbGeAlD
Bosutinib—YES1—endometrium—ovarian cancer	0.000139	0.000945	CbGeAlD
Bosutinib—ULK3—bone marrow—ovarian cancer	0.000139	0.000945	CbGeAlD
Bosutinib—MAP2K2—bone marrow—ovarian cancer	0.000139	0.000945	CbGeAlD
Bosutinib—BCR—testis—ovarian cancer	0.000139	0.000943	CbGeAlD
Bosutinib—NUAK2—testis—ovarian cancer	0.000139	0.000943	CbGeAlD
Bosutinib—MAP4K5—uterus—ovarian cancer	0.000139	0.000943	CbGeAlD
Bosutinib—CSNK1E—vagina—ovarian cancer	0.000138	0.00094	CbGeAlD
Bosutinib—MAP3K2—bone marrow—ovarian cancer	0.000138	0.000938	CbGeAlD
Bosutinib—MAP3K12—testis—ovarian cancer	0.000138	0.000936	CbGeAlD
Bosutinib—RPS6KB1—female reproductive system—ovarian cancer	0.000138	0.000936	CbGeAlD
Bosutinib—TAOK3—endometrium—ovarian cancer	0.000137	0.000933	CbGeAlD
Bosutinib—SIK1—female gonad—ovarian cancer	0.000137	0.000931	CbGeAlD
Bosutinib—IRAK4—female gonad—ovarian cancer	0.000137	0.000931	CbGeAlD
Bosutinib—FGR—female reproductive system—ovarian cancer	0.000137	0.00093	CbGeAlD
Bosutinib—MAP3K7—bone marrow—ovarian cancer	0.000137	0.000929	CbGeAlD
Bosutinib—AXL—female reproductive system—ovarian cancer	0.000136	0.000927	CbGeAlD
Bosutinib—Asthenia—Melphalan—ovarian cancer	0.000136	0.00115	CcSEcCtD
Bosutinib—IRAK4—vagina—ovarian cancer	0.000136	0.000926	CbGeAlD
Bosutinib—MAP2K5—uterine cervix—ovarian cancer	0.000136	0.000924	CbGeAlD
Bosutinib—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000136	0.00115	CcSEcCtD
Bosutinib—EPHA4—female gonad—ovarian cancer	0.000136	0.000922	CbGeAlD
Bosutinib—TBK1—bone marrow—ovarian cancer	0.000135	0.000919	CbGeAlD
Bosutinib—MAP2K1—testis—ovarian cancer	0.000135	0.000917	CbGeAlD
Bosutinib—STK35—testis—ovarian cancer	0.000135	0.000917	CbGeAlD
Bosutinib—ABL1—myometrium—ovarian cancer	0.000135	0.000916	CbGeAlD
Bosutinib—EPHA4—vagina—ovarian cancer	0.000135	0.000916	CbGeAlD
Bosutinib—Pruritus—Melphalan—ovarian cancer	0.000134	0.00114	CcSEcCtD
Bosutinib—ERBB3—female gonad—ovarian cancer	0.000134	0.000913	CbGeAlD
Bosutinib—CSK—testis—ovarian cancer	0.000134	0.000911	CbGeAlD
Bosutinib—MAP2K2—female gonad—ovarian cancer	0.000134	0.000911	CbGeAlD
Bosutinib—ULK3—female gonad—ovarian cancer	0.000134	0.000911	CbGeAlD
Bosutinib—Dysgeusia—Paclitaxel—ovarian cancer	0.000134	0.00113	CcSEcCtD
Bosutinib—STK25—lymph node—ovarian cancer	0.000134	0.000908	CbGeAlD
Bosutinib—CSNK1A1—testis—ovarian cancer	0.000133	0.000905	CbGeAlD
Bosutinib—Hepatitis—Docetaxel—ovarian cancer	0.000133	0.00113	CcSEcCtD
Bosutinib—ULK3—vagina—ovarian cancer	0.000133	0.000905	CbGeAlD
Bosutinib—MAP3K2—female gonad—ovarian cancer	0.000133	0.000904	CbGeAlD
Bosutinib—Diarrhoea—Topotecan—ovarian cancer	0.000133	0.00112	CcSEcCtD
Bosutinib—CSF1R—uterine cervix—ovarian cancer	0.000133	0.000902	CbGeAlD
Bosutinib—EPHA3—lymph node—ovarian cancer	0.000133	0.000902	CbGeAlD
Bosutinib—IRAK1—bone marrow—ovarian cancer	0.000132	0.0009	CbGeAlD
Bosutinib—HCK—testis—ovarian cancer	0.000132	0.0009	CbGeAlD
Bosutinib—CLK1—testis—ovarian cancer	0.000132	0.0009	CbGeAlD
Bosutinib—Back pain—Paclitaxel—ovarian cancer	0.000132	0.00112	CcSEcCtD
Bosutinib—Urticaria—Vinorelbine—ovarian cancer	0.000132	0.00111	CcSEcCtD
Bosutinib—MAP3K7—female gonad—ovarian cancer	0.000132	0.000896	CbGeAlD
Bosutinib—Urinary tract disorder—Docetaxel—ovarian cancer	0.000131	0.00111	CcSEcCtD
Bosutinib—ABL2—testis—ovarian cancer	0.000131	0.000894	CbGeAlD
Bosutinib—Body temperature increased—Vinorelbine—ovarian cancer	0.000131	0.00111	CcSEcCtD
Bosutinib—Abdominal pain—Vinorelbine—ovarian cancer	0.000131	0.00111	CcSEcCtD
Bosutinib—Oedema peripheral—Docetaxel—ovarian cancer	0.000131	0.00111	CcSEcCtD
Bosutinib—MAP3K7—vagina—ovarian cancer	0.000131	0.00089	CbGeAlD
Bosutinib—Connective tissue disorder—Docetaxel—ovarian cancer	0.000131	0.00111	CcSEcCtD
Bosutinib—Urethral disorder—Docetaxel—ovarian cancer	0.00013	0.0011	CcSEcCtD
Bosutinib—EPHB4—female reproductive system—ovarian cancer	0.00013	0.000885	CbGeAlD
Bosutinib—TBK1—female gonad—ovarian cancer	0.00013	0.000885	CbGeAlD
Bosutinib—PTK2—female gonad—ovarian cancer	0.00013	0.000885	CbGeAlD
Bosutinib—Renal failure acute—Doxorubicin—ovarian cancer	0.00013	0.0011	CcSEcCtD
Bosutinib—RPS6KB1—bone marrow—ovarian cancer	0.00013	0.000884	CbGeAlD
Bosutinib—Diarrhoea—Melphalan—ovarian cancer	0.00013	0.0011	CcSEcCtD
Bosutinib—PLK2—lymph node—ovarian cancer	0.00013	0.000883	CbGeAlD
Bosutinib—CAMK2G—testis—ovarian cancer	0.00013	0.000883	CbGeAlD
Bosutinib—BMP2K—testis—ovarian cancer	0.00013	0.000883	CbGeAlD
Bosutinib—Gastrointestinal haemorrhage—Epirubicin—ovarian cancer	0.00013	0.0011	CcSEcCtD
Bosutinib—ABL1—embryo—ovarian cancer	0.00013	0.000881	CbGeAlD
Bosutinib—MAP2K5—decidua—ovarian cancer	0.000129	0.000881	CbGeAlD
Bosutinib—PTK2—vagina—ovarian cancer	0.000129	0.00088	CbGeAlD
Bosutinib—TBK1—vagina—ovarian cancer	0.000129	0.00088	CbGeAlD
Bosutinib—Nausea—Chlorambucil—ovarian cancer	0.000129	0.00109	CcSEcCtD
Bosutinib—FGR—bone marrow—ovarian cancer	0.000129	0.000878	CbGeAlD
Bosutinib—LCK—bone marrow—ovarian cancer	0.000129	0.000878	CbGeAlD
Bosutinib—SIK3—lymph node—ovarian cancer	0.000129	0.000877	CbGeAlD
Bosutinib—YES1—gonad—ovarian cancer	0.000129	0.000876	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Epirubicin—ovarian cancer	0.000129	0.0282	CbGdCrCtD
Bosutinib—LRRK2—testis—ovarian cancer	0.000129	0.000875	CbGeAlD
Bosutinib—EGFR—testis—ovarian cancer	0.000128	0.000872	CbGeAlD
Bosutinib—Dizziness—Topotecan—ovarian cancer	0.000128	0.00108	CcSEcCtD
Bosutinib—YES1—uterus—ovarian cancer	0.000128	0.000871	CbGeAlD
Bosutinib—EPHA2—female reproductive system—ovarian cancer	0.000128	0.000869	CbGeAlD
Bosutinib—STK10—gonad—ovarian cancer	0.000128	0.000868	CbGeAlD
Bosutinib—IRAK1—female gonad—ovarian cancer	0.000128	0.000868	CbGeAlD
Bosutinib—FYN—female reproductive system—ovarian cancer	0.000127	0.000867	CbGeAlD
Bosutinib—STK10—uterus—ovarian cancer	0.000127	0.000863	CbGeAlD
Bosutinib—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000127	0.00107	CcSEcCtD
Bosutinib—CSF1R—decidua—ovarian cancer	0.000126	0.00086	CbGeAlD
Bosutinib—TAOK3—uterus—ovarian cancer	0.000126	0.000859	CbGeAlD
Bosutinib—Anaemia—Paclitaxel—ovarian cancer	0.000126	0.00107	CcSEcCtD
Bosutinib—Renal impairment—Doxorubicin—ovarian cancer	0.000126	0.00107	CcSEcCtD
Bosutinib—Erythema multiforme—Docetaxel—ovarian cancer	0.000126	0.00106	CcSEcCtD
Bosutinib—PTK2B—testis—ovarian cancer	0.000125	0.000853	CbGeAlD
Bosutinib—Face oedema—Epirubicin—ovarian cancer	0.000125	0.00106	CcSEcCtD
Bosutinib—RPS6KB1—female gonad—ovarian cancer	0.000125	0.000852	CbGeAlD
Bosutinib—MAP3K3—female reproductive system—ovarian cancer	0.000125	0.000847	CbGeAlD
Bosutinib—MAP4K5—female reproductive system—ovarian cancer	0.000125	0.000847	CbGeAlD
Bosutinib—RPS6KB1—vagina—ovarian cancer	0.000124	0.000847	CbGeAlD
Bosutinib—FGR—female gonad—ovarian cancer	0.000124	0.000846	CbGeAlD
Bosutinib—LCK—female gonad—ovarian cancer	0.000124	0.000846	CbGeAlD
Bosutinib—STK4—lymph node—ovarian cancer	0.000124	0.000845	CbGeAlD
Bosutinib—AXL—female gonad—ovarian cancer	0.000124	0.000843	CbGeAlD
Bosutinib—SRC—gonad—ovarian cancer	0.000124	0.000843	CbGeAlD
Bosutinib—SLK—bone marrow—ovarian cancer	0.000124	0.000842	CbGeAlD
Bosutinib—FGR—vagina—ovarian cancer	0.000124	0.000841	CbGeAlD
Bosutinib—LCK—vagina—ovarian cancer	0.000124	0.000841	CbGeAlD
Bosutinib—Cardiac disorder—Docetaxel—ovarian cancer	0.000124	0.00105	CcSEcCtD
Bosutinib—CSNK1E—testis—ovarian cancer	0.000123	0.000839	CbGeAlD
Bosutinib—Vomiting—Topotecan—ovarian cancer	0.000123	0.00104	CcSEcCtD
Bosutinib—Malaise—Paclitaxel—ovarian cancer	0.000123	0.00104	CcSEcCtD
Bosutinib—AXL—vagina—ovarian cancer	0.000123	0.000838	CbGeAlD
Bosutinib—MAP2K5—endometrium—ovarian cancer	0.000123	0.000836	CbGeAlD
Bosutinib—EPHB4—bone marrow—ovarian cancer	0.000123	0.000836	CbGeAlD
Bosutinib—CAMK1D—lymph node—ovarian cancer	0.000123	0.000834	CbGeAlD
Bosutinib—CHEK2—Vindesine—Vinorelbine—ovarian cancer	0.000122	0.0268	CbGdCrCtD
Bosutinib—Leukopenia—Paclitaxel—ovarian cancer	0.000122	0.00104	CcSEcCtD
Bosutinib—Rash—Topotecan—ovarian cancer	0.000122	0.00103	CcSEcCtD
Bosutinib—Dermatitis—Topotecan—ovarian cancer	0.000122	0.00103	CcSEcCtD
Bosutinib—Blood creatinine increased—Epirubicin—ovarian cancer	0.000122	0.00103	CcSEcCtD
Bosutinib—Headache—Topotecan—ovarian cancer	0.000121	0.00103	CcSEcCtD
Bosutinib—SIK1—testis—ovarian cancer	0.000121	0.000826	CbGeAlD
Bosutinib—IRAK4—testis—ovarian cancer	0.000121	0.000826	CbGeAlD
Bosutinib—STK24—lymph node—ovarian cancer	0.000121	0.000825	CbGeAlD
Bosutinib—Vomiting—Melphalan—ovarian cancer	0.000121	0.00102	CcSEcCtD
Bosutinib—Dehydration—Epirubicin—ovarian cancer	0.000121	0.00102	CcSEcCtD
Bosutinib—FYN—bone marrow—ovarian cancer	0.00012	0.000819	CbGeAlD
Bosutinib—Immune system disorder—Docetaxel—ovarian cancer	0.00012	0.00102	CcSEcCtD
Bosutinib—EPHA4—testis—ovarian cancer	0.00012	0.000818	CbGeAlD
Bosutinib—Gastrointestinal haemorrhage—Doxorubicin—ovarian cancer	0.00012	0.00102	CcSEcCtD
Bosutinib—CSF1R—endometrium—ovarian cancer	0.00012	0.000816	CbGeAlD
Bosutinib—Mediastinal disorder—Docetaxel—ovarian cancer	0.00012	0.00102	CcSEcCtD
Bosutinib—Rash—Melphalan—ovarian cancer	0.00012	0.00101	CcSEcCtD
Bosutinib—Dermatitis—Melphalan—ovarian cancer	0.00012	0.00101	CcSEcCtD
Bosutinib—SLK—female gonad—ovarian cancer	0.000119	0.000812	CbGeAlD
Bosutinib—Cough—Paclitaxel—ovarian cancer	0.000119	0.00101	CcSEcCtD
Bosutinib—WEE1—Daunorubicin—Doxorubicin—ovarian cancer	0.000119	0.0261	CbGdCrCtD
Bosutinib—ERBB3—testis—ovarian cancer	0.000119	0.00081	CbGeAlD
Bosutinib—Asthenia—Vinorelbine—ovarian cancer	0.000119	0.00101	CcSEcCtD
Bosutinib—MAP2K2—testis—ovarian cancer	0.000119	0.000808	CbGeAlD
Bosutinib—ULK3—testis—ovarian cancer	0.000119	0.000808	CbGeAlD
Bosutinib—PDGFRB—epithelium—ovarian cancer	0.000119	0.000807	CbGeAlD
Bosutinib—SLK—vagina—ovarian cancer	0.000119	0.000807	CbGeAlD
Bosutinib—Abdominal pain upper—Epirubicin—ovarian cancer	0.000119	0.001	CcSEcCtD
Bosutinib—EPHB4—female gonad—ovarian cancer	0.000118	0.000806	CbGeAlD
Bosutinib—MAP3K2—testis—ovarian cancer	0.000118	0.000802	CbGeAlD
Bosutinib—EPHB4—vagina—ovarian cancer	0.000118	0.000801	CbGeAlD
Bosutinib—PDGFRB—uterine cervix—ovarian cancer	0.000118	0.0008	CbGeAlD
Bosutinib—MAP4K5—bone marrow—ovarian cancer	0.000118	0.0008	CbGeAlD
Bosutinib—MAP3K3—bone marrow—ovarian cancer	0.000118	0.0008	CbGeAlD
Bosutinib—FER—lymph node—ovarian cancer	0.000117	0.000798	CbGeAlD
Bosutinib—ALK—lymph node—ovarian cancer	0.000117	0.000798	CbGeAlD
Bosutinib—Pruritus—Vinorelbine—ovarian cancer	0.000117	0.000993	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000117	0.000989	CcSEcCtD
Bosutinib—MAP3K7—testis—ovarian cancer	0.000117	0.000794	CbGeAlD
Bosutinib—Myalgia—Paclitaxel—ovarian cancer	0.000116	0.000985	CcSEcCtD
Bosutinib—Arthralgia—Paclitaxel—ovarian cancer	0.000116	0.000985	CcSEcCtD
Bosutinib—Chest pain—Paclitaxel—ovarian cancer	0.000116	0.000985	CcSEcCtD
Bosutinib—EPHA2—female gonad—ovarian cancer	0.000116	0.00079	CbGeAlD
Bosutinib—Nasopharyngitis—Epirubicin—ovarian cancer	0.000116	0.000982	CcSEcCtD
Bosutinib—FYN—female gonad—ovarian cancer	0.000116	0.000789	CbGeAlD
Bosutinib—Face oedema—Doxorubicin—ovarian cancer	0.000116	0.000981	CcSEcCtD
Bosutinib—Malnutrition—Docetaxel—ovarian cancer	0.000116	0.00098	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000116	0.000978	CcSEcCtD
Bosutinib—EPHA2—vagina—ovarian cancer	0.000115	0.000786	CbGeAlD
Bosutinib—TBK1—testis—ovarian cancer	0.000115	0.000785	CbGeAlD
Bosutinib—PTK2—testis—ovarian cancer	0.000115	0.000785	CbGeAlD
Bosutinib—FYN—vagina—ovarian cancer	0.000115	0.000784	CbGeAlD
Bosutinib—Nausea—Topotecan—ovarian cancer	0.000115	0.000975	CcSEcCtD
Bosutinib—YES1—female reproductive system—ovarian cancer	0.000115	0.000783	CbGeAlD
Bosutinib—Discomfort—Paclitaxel—ovarian cancer	0.000115	0.000973	CcSEcCtD
Bosutinib—MAP4K1—lymph node—ovarian cancer	0.000115	0.000782	CbGeAlD
Bosutinib—Gastritis—Epirubicin—ovarian cancer	0.000115	0.000972	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000114	0.000968	CcSEcCtD
Bosutinib—BTK—lymph node—ovarian cancer	0.000114	0.000778	CbGeAlD
Bosutinib—STK10—female reproductive system—ovarian cancer	0.000114	0.000776	CbGeAlD
Bosutinib—TAOK3—female reproductive system—ovarian cancer	0.000114	0.000773	CbGeAlD
Bosutinib—Diarrhoea—Vinorelbine—ovarian cancer	0.000113	0.00096	CcSEcCtD
Bosutinib—Dysgeusia—Docetaxel—ovarian cancer	0.000113	0.00096	CcSEcCtD
Bosutinib—MAP4K5—female gonad—ovarian cancer	0.000113	0.000771	CbGeAlD
Bosutinib—MAP3K3—female gonad—ovarian cancer	0.000113	0.000771	CbGeAlD
Bosutinib—IRAK1—testis—ovarian cancer	0.000113	0.00077	CbGeAlD
Bosutinib—Nausea—Melphalan—ovarian cancer	0.000113	0.000954	CcSEcCtD
Bosutinib—TNK2—lymph node—ovarian cancer	0.000113	0.000767	CbGeAlD
Bosutinib—MAP4K5—vagina—ovarian cancer	0.000113	0.000766	CbGeAlD
Bosutinib—MAP3K3—vagina—ovarian cancer	0.000113	0.000766	CbGeAlD
Bosutinib—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000112	0.000952	CcSEcCtD
Bosutinib—Influenza—Epirubicin—ovarian cancer	0.000112	0.000949	CcSEcCtD
Bosutinib—PDGFRB—decidua—ovarian cancer	0.000112	0.000762	CbGeAlD
Bosutinib—Back pain—Docetaxel—ovarian cancer	0.000112	0.000948	CcSEcCtD
Bosutinib—Dehydration—Doxorubicin—ovarian cancer	0.000112	0.000945	CcSEcCtD
Bosutinib—Oedema—Paclitaxel—ovarian cancer	0.000112	0.000944	CcSEcCtD
Bosutinib—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000112	0.000944	CcSEcCtD
Bosutinib—CSF1R—gonad—ovarian cancer	0.000111	0.000757	CbGeAlD
Bosutinib—MAP4K2—lymph node—ovarian cancer	0.000111	0.000756	CbGeAlD
Bosutinib—RPS6KB1—testis—ovarian cancer	0.000111	0.000755	CbGeAlD
Bosutinib—Infection—Paclitaxel—ovarian cancer	0.000111	0.000938	CcSEcCtD
Bosutinib—SRC—female reproductive system—ovarian cancer	0.000111	0.000753	CbGeAlD
Bosutinib—CSF1R—uterus—ovarian cancer	0.000111	0.000752	CbGeAlD
Bosutinib—LCK—testis—ovarian cancer	0.00011	0.000751	CbGeAlD
Bosutinib—FGR—testis—ovarian cancer	0.00011	0.000751	CbGeAlD
Bosutinib—AXL—testis—ovarian cancer	0.00011	0.000748	CbGeAlD
Bosutinib—Dizziness—Vinorelbine—ovarian cancer	0.00011	0.000928	CcSEcCtD
Bosutinib—STK3—lymph node—ovarian cancer	0.00011	0.000746	CbGeAlD
Bosutinib—Abdominal pain upper—Doxorubicin—ovarian cancer	0.00011	0.000928	CcSEcCtD
Bosutinib—Nervous system disorder—Paclitaxel—ovarian cancer	0.000109	0.000926	CcSEcCtD
Bosutinib—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000109	0.000924	CcSEcCtD
Bosutinib—YES1—bone marrow—ovarian cancer	0.000109	0.000739	CbGeAlD
Bosutinib—Skin disorder—Paclitaxel—ovarian cancer	0.000108	0.000917	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000108	0.000915	CcSEcCtD
Bosutinib—Bronchitis—Epirubicin—ovarian cancer	0.000108	0.000913	CcSEcCtD
Bosutinib—STK10—bone marrow—ovarian cancer	0.000108	0.000732	CbGeAlD
Bosutinib—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000107	0.000909	CcSEcCtD
Bosutinib—TAOK3—bone marrow—ovarian cancer	0.000107	0.000729	CbGeAlD
Bosutinib—Anaemia—Docetaxel—ovarian cancer	0.000107	0.000906	CcSEcCtD
Bosutinib—Pancytopenia—Epirubicin—ovarian cancer	0.000106	0.000901	CcSEcCtD
Bosutinib—PDGFRB—endometrium—ovarian cancer	0.000106	0.000724	CbGeAlD
Bosutinib—Gastritis—Doxorubicin—ovarian cancer	0.000106	0.000899	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000106	0.000896	CcSEcCtD
Bosutinib—SLK—testis—ovarian cancer	0.000106	0.00072	CbGeAlD
Bosutinib—Vomiting—Vinorelbine—ovarian cancer	0.000105	0.000892	CcSEcCtD
Bosutinib—BMPR2—lymph node—ovarian cancer	0.000105	0.000715	CbGeAlD
Bosutinib—EPHB4—testis—ovarian cancer	0.000105	0.000715	CbGeAlD
Bosutinib—Neutropenia—Epirubicin—ovarian cancer	0.000105	0.000887	CcSEcCtD
Bosutinib—ABL1—uterine cervix—ovarian cancer	0.000105	0.000713	CbGeAlD
Bosutinib—YES1—female gonad—ovarian cancer	0.000105	0.000712	CbGeAlD
Bosutinib—Rash—Vinorelbine—ovarian cancer	0.000105	0.000885	CcSEcCtD
Bosutinib—Dermatitis—Vinorelbine—ovarian cancer	0.000104	0.000884	CcSEcCtD
Bosutinib—EPHB3—lymph node—ovarian cancer	0.000104	0.00071	CbGeAlD
Bosutinib—STK36—lymph node—ovarian cancer	0.000104	0.00071	CbGeAlD
Bosutinib—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000104	0.000882	CcSEcCtD
Bosutinib—YES1—vagina—ovarian cancer	0.000104	0.000708	CbGeAlD
Bosutinib—Headache—Vinorelbine—ovarian cancer	0.000104	0.000879	CcSEcCtD
Bosutinib—Influenza—Doxorubicin—ovarian cancer	0.000104	0.000878	CcSEcCtD
Bosutinib—STK10—female gonad—ovarian cancer	0.000104	0.000706	CbGeAlD
Bosutinib—Leukopenia—Docetaxel—ovarian cancer	0.000104	0.000878	CcSEcCtD
Bosutinib—TAOK3—female gonad—ovarian cancer	0.000103	0.000703	CbGeAlD
Bosutinib—STK10—vagina—ovarian cancer	0.000103	0.000701	CbGeAlD
Bosutinib—MERTK—lymph node—ovarian cancer	0.000103	0.000701	CbGeAlD
Bosutinib—EPHA2—testis—ovarian cancer	0.000103	0.000701	CbGeAlD
Bosutinib—FYN—testis—ovarian cancer	0.000103	0.0007	CbGeAlD
Bosutinib—TAOK3—vagina—ovarian cancer	0.000103	0.000699	CbGeAlD
Bosutinib—MAP2K5—female reproductive system—ovarian cancer	0.000102	0.000693	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000102	0.00086	CcSEcCtD
Bosutinib—MAP4K4—lymph node—ovarian cancer	0.000101	0.000688	CbGeAlD
Bosutinib—Cough—Docetaxel—ovarian cancer	0.000101	0.000856	CcSEcCtD
Bosutinib—SRC—female gonad—ovarian cancer	0.000101	0.000685	CbGeAlD
Bosutinib—Pneumonia—Epirubicin—ovarian cancer	0.000101	0.000851	CcSEcCtD
Bosutinib—MAP4K5—testis—ovarian cancer	0.000101	0.000684	CbGeAlD
Bosutinib—MAP3K3—testis—ovarian cancer	0.000101	0.000684	CbGeAlD
Bosutinib—BCR—lymph node—ovarian cancer	0.0001	0.000683	CbGeAlD
Bosutinib—NUAK2—lymph node—ovarian cancer	0.0001	0.000683	CbGeAlD
Bosutinib—Infestation NOS—Epirubicin—ovarian cancer	0.0001	0.000846	CcSEcCtD
Bosutinib—Infestation—Epirubicin—ovarian cancer	0.0001	0.000846	CcSEcCtD
Bosutinib—ABL1—decidua—ovarian cancer	9.99e-05	0.000679	CbGeAlD
Bosutinib—Bronchitis—Doxorubicin—ovarian cancer	9.98e-05	0.000845	CcSEcCtD
Bosutinib—MAP3K12—lymph node—ovarian cancer	9.98e-05	0.000679	CbGeAlD
Bosutinib—Dyspnoea—Paclitaxel—ovarian cancer	9.94e-05	0.000842	CcSEcCtD
Bosutinib—CSF1R—female reproductive system—ovarian cancer	9.94e-05	0.000676	CbGeAlD
Bosutinib—PDGFRB—gonad—ovarian cancer	9.87e-05	0.000671	CbGeAlD
Bosutinib—Chest pain—Docetaxel—ovarian cancer	9.86e-05	0.000835	CcSEcCtD
Bosutinib—Arthralgia—Docetaxel—ovarian cancer	9.86e-05	0.000835	CcSEcCtD
Bosutinib—Myalgia—Docetaxel—ovarian cancer	9.86e-05	0.000835	CcSEcCtD
Bosutinib—Pancytopenia—Doxorubicin—ovarian cancer	9.85e-05	0.000834	CcSEcCtD
Bosutinib—Nausea—Vinorelbine—ovarian cancer	9.85e-05	0.000834	CcSEcCtD
Bosutinib—Renal failure—Epirubicin—ovarian cancer	9.83e-05	0.000832	CcSEcCtD
Bosutinib—PDGFRB—uterus—ovarian cancer	9.8e-05	0.000667	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	9.79e-05	0.000829	CcSEcCtD
Bosutinib—MAP2K1—lymph node—ovarian cancer	9.77e-05	0.000665	CbGeAlD
Bosutinib—STK35—lymph node—ovarian cancer	9.77e-05	0.000665	CbGeAlD
Bosutinib—CSK—lymph node—ovarian cancer	9.71e-05	0.000661	CbGeAlD
Bosutinib—Neutropenia—Doxorubicin—ovarian cancer	9.7e-05	0.000821	CcSEcCtD
Bosutinib—Decreased appetite—Paclitaxel—ovarian cancer	9.7e-05	0.000821	CcSEcCtD
Bosutinib—CSNK1A1—lymph node—ovarian cancer	9.65e-05	0.000656	CbGeAlD
Bosutinib—Upper respiratory tract infection—Doxorubicin—ovarian cancer	9.64e-05	0.000816	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	9.63e-05	0.000815	CcSEcCtD
Bosutinib—Fatigue—Paclitaxel—ovarian cancer	9.62e-05	0.000814	CcSEcCtD
Bosutinib—CHEK2—Paclitaxel—Docetaxel—ovarian cancer	9.61e-05	0.0211	CbGdCrCtD
Bosutinib—HCK—lymph node—ovarian cancer	9.59e-05	0.000652	CbGeAlD
Bosutinib—CLK1—lymph node—ovarian cancer	9.59e-05	0.000652	CbGeAlD
Bosutinib—Pain—Paclitaxel—ovarian cancer	9.54e-05	0.000807	CcSEcCtD
Bosutinib—ABL2—lymph node—ovarian cancer	9.52e-05	0.000648	CbGeAlD
Bosutinib—ABL1—endometrium—ovarian cancer	9.48e-05	0.000645	CbGeAlD
Bosutinib—Hepatobiliary disease—Epirubicin—ovarian cancer	9.46e-05	0.0008	CcSEcCtD
Bosutinib—Anaphylactic shock—Docetaxel—ovarian cancer	9.45e-05	0.0008	CcSEcCtD
Bosutinib—Oedema—Docetaxel—ovarian cancer	9.45e-05	0.0008	CcSEcCtD
Bosutinib—CAMK2G—lymph node—ovarian cancer	9.41e-05	0.00064	CbGeAlD
Bosutinib—BMP2K—lymph node—ovarian cancer	9.41e-05	0.00064	CbGeAlD
Bosutinib—Infection—Docetaxel—ovarian cancer	9.39e-05	0.000795	CcSEcCtD
Bosutinib—CSF1R—bone marrow—ovarian cancer	9.38e-05	0.000638	CbGeAlD
Bosutinib—Agranulocytosis—Epirubicin—ovarian cancer	9.33e-05	0.00079	CcSEcCtD
Bosutinib—LRRK2—lymph node—ovarian cancer	9.32e-05	0.000634	CbGeAlD
Bosutinib—Pneumonia—Doxorubicin—ovarian cancer	9.31e-05	0.000788	CcSEcCtD
Bosutinib—EGFR—lymph node—ovarian cancer	9.3e-05	0.000632	CbGeAlD
Bosutinib—YES1—testis—ovarian cancer	9.28e-05	0.000632	CbGeAlD
Bosutinib—Nervous system disorder—Docetaxel—ovarian cancer	9.27e-05	0.000785	CcSEcCtD
Bosutinib—MAP2K5—female gonad—ovarian cancer	9.26e-05	0.00063	CbGeAlD
Bosutinib—Thrombocytopenia—Docetaxel—ovarian cancer	9.26e-05	0.000783	CcSEcCtD
Bosutinib—Infestation—Doxorubicin—ovarian cancer	9.25e-05	0.000783	CcSEcCtD
Bosutinib—Infestation NOS—Doxorubicin—ovarian cancer	9.25e-05	0.000783	CcSEcCtD
Bosutinib—MAP2K5—vagina—ovarian cancer	9.21e-05	0.000626	CbGeAlD
Bosutinib—STK10—testis—ovarian cancer	9.2e-05	0.000626	CbGeAlD
Bosutinib—Feeling abnormal—Paclitaxel—ovarian cancer	9.19e-05	0.000778	CcSEcCtD
Bosutinib—Skin disorder—Docetaxel—ovarian cancer	9.18e-05	0.000777	CcSEcCtD
Bosutinib—TAOK3—testis—ovarian cancer	9.17e-05	0.000624	CbGeAlD
Bosutinib—Gastrointestinal pain—Paclitaxel—ovarian cancer	9.12e-05	0.000772	CcSEcCtD
Bosutinib—Renal failure—Doxorubicin—ovarian cancer	9.09e-05	0.00077	CcSEcCtD
Bosutinib—PTK2B—lymph node—ovarian cancer	9.09e-05	0.000618	CbGeAlD
Bosutinib—CSF1R—female gonad—ovarian cancer	9.04e-05	0.000615	CbGeAlD
Bosutinib—CSF1R—vagina—ovarian cancer	8.99e-05	0.000611	CbGeAlD
Bosutinib—Hepatitis—Epirubicin—ovarian cancer	8.98e-05	0.00076	CcSEcCtD
Bosutinib—CSNK1E—lymph node—ovarian cancer	8.94e-05	0.000608	CbGeAlD
Bosutinib—SRC—testis—ovarian cancer	8.93e-05	0.000608	CbGeAlD
Bosutinib—Urinary tract disorder—Epirubicin—ovarian cancer	8.86e-05	0.00075	CcSEcCtD
Bosutinib—Urticaria—Paclitaxel—ovarian cancer	8.86e-05	0.00075	CcSEcCtD
Bosutinib—Oedema peripheral—Epirubicin—ovarian cancer	8.84e-05	0.000748	CcSEcCtD
Bosutinib—Connective tissue disorder—Epirubicin—ovarian cancer	8.82e-05	0.000746	CcSEcCtD
Bosutinib—Body temperature increased—Paclitaxel—ovarian cancer	8.82e-05	0.000746	CcSEcCtD
Bosutinib—Abdominal pain—Paclitaxel—ovarian cancer	8.82e-05	0.000746	CcSEcCtD
Bosutinib—PDGFRB—female reproductive system—ovarian cancer	8.81e-05	0.000599	CbGeAlD
Bosutinib—SIK1—lymph node—ovarian cancer	8.8e-05	0.000599	CbGeAlD
Bosutinib—IRAK4—lymph node—ovarian cancer	8.8e-05	0.000599	CbGeAlD
Bosutinib—Urethral disorder—Epirubicin—ovarian cancer	8.8e-05	0.000745	CcSEcCtD
Bosutinib—ABL1—gonad—ovarian cancer	8.79e-05	0.000598	CbGeAlD
Bosutinib—Hepatobiliary disease—Doxorubicin—ovarian cancer	8.75e-05	0.000741	CcSEcCtD
Bosutinib—ABL1—uterus—ovarian cancer	8.74e-05	0.000594	CbGeAlD
Bosutinib—EPHA4—lymph node—ovarian cancer	8.71e-05	0.000593	CbGeAlD
Bosutinib—Agranulocytosis—Doxorubicin—ovarian cancer	8.63e-05	0.000731	CcSEcCtD
Bosutinib—ERBB3—lymph node—ovarian cancer	8.63e-05	0.000587	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Docetaxel—ovarian cancer	8.61e-05	0.000729	CcSEcCtD
Bosutinib—ULK3—lymph node—ovarian cancer	8.61e-05	0.000585	CbGeAlD
Bosutinib—MAP2K2—lymph node—ovarian cancer	8.61e-05	0.000585	CbGeAlD
Bosutinib—MAP3K2—lymph node—ovarian cancer	8.54e-05	0.000581	CbGeAlD
Bosutinib—Erythema multiforme—Epirubicin—ovarian cancer	8.49e-05	0.000718	CcSEcCtD
Bosutinib—MAP3K7—lymph node—ovarian cancer	8.46e-05	0.000576	CbGeAlD
Bosutinib—Dyspnoea—Docetaxel—ovarian cancer	8.43e-05	0.000713	CcSEcCtD
Bosutinib—Tinnitus—Epirubicin—ovarian cancer	8.37e-05	0.000708	CcSEcCtD
Bosutinib—TBK1—lymph node—ovarian cancer	8.37e-05	0.000569	CbGeAlD
Bosutinib—PTK2—lymph node—ovarian cancer	8.37e-05	0.000569	CbGeAlD
Bosutinib—Cardiac disorder—Epirubicin—ovarian cancer	8.33e-05	0.000705	CcSEcCtD
Bosutinib—PDGFRB—bone marrow—ovarian cancer	8.32e-05	0.000566	CbGeAlD
Bosutinib—Hepatitis—Doxorubicin—ovarian cancer	8.31e-05	0.000703	CcSEcCtD
Bosutinib—Decreased appetite—Docetaxel—ovarian cancer	8.22e-05	0.000696	CcSEcCtD
Bosutinib—MAP2K5—testis—ovarian cancer	8.22e-05	0.000559	CbGeAlD
Bosutinib—IRAK1—lymph node—ovarian cancer	8.2e-05	0.000558	CbGeAlD
Bosutinib—Urinary tract disorder—Doxorubicin—ovarian cancer	8.2e-05	0.000694	CcSEcCtD
Bosutinib—Oedema peripheral—Doxorubicin—ovarian cancer	8.18e-05	0.000692	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Docetaxel—ovarian cancer	8.16e-05	0.000691	CcSEcCtD
Bosutinib—Connective tissue disorder—Doxorubicin—ovarian cancer	8.16e-05	0.000691	CcSEcCtD
Bosutinib—Fatigue—Docetaxel—ovarian cancer	8.15e-05	0.00069	CcSEcCtD
Bosutinib—Urethral disorder—Doxorubicin—ovarian cancer	8.14e-05	0.000689	CcSEcCtD
Bosutinib—Immune system disorder—Epirubicin—ovarian cancer	8.11e-05	0.000686	CcSEcCtD
Bosutinib—Mediastinal disorder—Epirubicin—ovarian cancer	8.09e-05	0.000685	CcSEcCtD
Bosutinib—Pain—Docetaxel—ovarian cancer	8.08e-05	0.000684	CcSEcCtD
Bosutinib—RPS6KB1—lymph node—ovarian cancer	8.05e-05	0.000548	CbGeAlD
Bosutinib—CSF1R—testis—ovarian cancer	8.02e-05	0.000545	CbGeAlD
Bosutinib—PDGFRB—female gonad—ovarian cancer	8.02e-05	0.000545	CbGeAlD
Bosutinib—Asthenia—Paclitaxel—ovarian cancer	8e-05	0.000677	CcSEcCtD
Bosutinib—LCK—lymph node—ovarian cancer	8e-05	0.000544	CbGeAlD
Bosutinib—FGR—lymph node—ovarian cancer	8e-05	0.000544	CbGeAlD
Bosutinib—PDGFRB—vagina—ovarian cancer	7.97e-05	0.000542	CbGeAlD
Bosutinib—AXL—lymph node—ovarian cancer	7.97e-05	0.000542	CbGeAlD
Bosutinib—Pruritus—Paclitaxel—ovarian cancer	7.89e-05	0.000668	CcSEcCtD
Bosutinib—ERBB3—Vinblastine—Vinorelbine—ovarian cancer	7.87e-05	0.0172	CbGdCrCtD
Bosutinib—ABL1—female reproductive system—ovarian cancer	7.85e-05	0.000534	CbGeAlD
Bosutinib—Erythema multiforme—Doxorubicin—ovarian cancer	7.85e-05	0.000665	CcSEcCtD
Bosutinib—Malnutrition—Epirubicin—ovarian cancer	7.81e-05	0.000661	CcSEcCtD
Bosutinib—Feeling abnormal—Docetaxel—ovarian cancer	7.79e-05	0.000659	CcSEcCtD
Bosutinib—Tinnitus—Doxorubicin—ovarian cancer	7.74e-05	0.000655	CcSEcCtD
Bosutinib—Gastrointestinal pain—Docetaxel—ovarian cancer	7.73e-05	0.000654	CcSEcCtD
Bosutinib—Cardiac disorder—Doxorubicin—ovarian cancer	7.71e-05	0.000652	CcSEcCtD
Bosutinib—SLK—lymph node—ovarian cancer	7.67e-05	0.000522	CbGeAlD
Bosutinib—Dysgeusia—Epirubicin—ovarian cancer	7.65e-05	0.000648	CcSEcCtD
Bosutinib—Diarrhoea—Paclitaxel—ovarian cancer	7.63e-05	0.000646	CcSEcCtD
Bosutinib—EPHB4—lymph node—ovarian cancer	7.61e-05	0.000518	CbGeAlD
Bosutinib—Back pain—Epirubicin—ovarian cancer	7.56e-05	0.00064	CcSEcCtD
Bosutinib—Immune system disorder—Doxorubicin—ovarian cancer	7.5e-05	0.000635	CcSEcCtD
Bosutinib—Mediastinal disorder—Doxorubicin—ovarian cancer	7.49e-05	0.000633	CcSEcCtD
Bosutinib—Body temperature increased—Docetaxel—ovarian cancer	7.47e-05	0.000633	CcSEcCtD
Bosutinib—Abdominal pain—Docetaxel—ovarian cancer	7.47e-05	0.000633	CcSEcCtD
Bosutinib—EPHA2—lymph node—ovarian cancer	7.47e-05	0.000508	CbGeAlD
Bosutinib—FYN—lymph node—ovarian cancer	7.46e-05	0.000507	CbGeAlD
Bosutinib—ABL1—bone marrow—ovarian cancer	7.42e-05	0.000504	CbGeAlD
Bosutinib—Dizziness—Paclitaxel—ovarian cancer	7.38e-05	0.000624	CcSEcCtD
Bosutinib—MAP4K5—lymph node—ovarian cancer	7.29e-05	0.000496	CbGeAlD
Bosutinib—MAP3K3—lymph node—ovarian cancer	7.29e-05	0.000496	CbGeAlD
Bosutinib—Ill-defined disorder—Epirubicin—ovarian cancer	7.25e-05	0.000614	CcSEcCtD
Bosutinib—Malnutrition—Doxorubicin—ovarian cancer	7.23e-05	0.000612	CcSEcCtD
Bosutinib—Anaemia—Epirubicin—ovarian cancer	7.22e-05	0.000611	CcSEcCtD
Bosutinib—ABL1—female gonad—ovarian cancer	7.15e-05	0.000486	CbGeAlD
Bosutinib—PDGFRB—testis—ovarian cancer	7.11e-05	0.000484	CbGeAlD
Bosutinib—ABL1—vagina—ovarian cancer	7.1e-05	0.000483	CbGeAlD
Bosutinib—Vomiting—Paclitaxel—ovarian cancer	7.09e-05	0.0006	CcSEcCtD
Bosutinib—Dysgeusia—Doxorubicin—ovarian cancer	7.08e-05	0.000599	CcSEcCtD
Bosutinib—Malaise—Epirubicin—ovarian cancer	7.05e-05	0.000596	CcSEcCtD
Bosutinib—Rash—Paclitaxel—ovarian cancer	7.03e-05	0.000595	CcSEcCtD
Bosutinib—Dermatitis—Paclitaxel—ovarian cancer	7.03e-05	0.000595	CcSEcCtD
Bosutinib—Leukopenia—Epirubicin—ovarian cancer	6.99e-05	0.000592	CcSEcCtD
Bosutinib—Back pain—Doxorubicin—ovarian cancer	6.99e-05	0.000592	CcSEcCtD
Bosutinib—Headache—Paclitaxel—ovarian cancer	6.99e-05	0.000591	CcSEcCtD
Bosutinib—Cough—Epirubicin—ovarian cancer	6.82e-05	0.000577	CcSEcCtD
Bosutinib—Asthenia—Docetaxel—ovarian cancer	6.78e-05	0.000574	CcSEcCtD
Bosutinib—YES1—lymph node—ovarian cancer	6.73e-05	0.000458	CbGeAlD
Bosutinib—Ill-defined disorder—Doxorubicin—ovarian cancer	6.71e-05	0.000568	CcSEcCtD
Bosutinib—Pruritus—Docetaxel—ovarian cancer	6.69e-05	0.000566	CcSEcCtD
Bosutinib—Anaemia—Doxorubicin—ovarian cancer	6.68e-05	0.000566	CcSEcCtD
Bosutinib—STK10—lymph node—ovarian cancer	6.67e-05	0.000454	CbGeAlD
Bosutinib—Chest pain—Epirubicin—ovarian cancer	6.65e-05	0.000563	CcSEcCtD
Bosutinib—Arthralgia—Epirubicin—ovarian cancer	6.65e-05	0.000563	CcSEcCtD
Bosutinib—Myalgia—Epirubicin—ovarian cancer	6.65e-05	0.000563	CcSEcCtD
Bosutinib—TAOK3—lymph node—ovarian cancer	6.64e-05	0.000452	CbGeAlD
Bosutinib—Nausea—Paclitaxel—ovarian cancer	6.63e-05	0.000561	CcSEcCtD
Bosutinib—CHEK2—Vincristine—Vinorelbine—ovarian cancer	6.61e-05	0.0145	CbGdCrCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	6.61e-05	0.000559	CcSEcCtD
Bosutinib—Discomfort—Epirubicin—ovarian cancer	6.57e-05	0.000556	CcSEcCtD
Bosutinib—Malaise—Doxorubicin—ovarian cancer	6.52e-05	0.000552	CcSEcCtD
Bosutinib—SRC—lymph node—ovarian cancer	6.47e-05	0.00044	CbGeAlD
Bosutinib—Leukopenia—Doxorubicin—ovarian cancer	6.47e-05	0.000548	CcSEcCtD
Bosutinib—Diarrhoea—Docetaxel—ovarian cancer	6.47e-05	0.000547	CcSEcCtD
Bosutinib—Anaphylactic shock—Epirubicin—ovarian cancer	6.38e-05	0.00054	CcSEcCtD
Bosutinib—Oedema—Epirubicin—ovarian cancer	6.38e-05	0.00054	CcSEcCtD
Bosutinib—ABL1—testis—ovarian cancer	6.34e-05	0.000431	CbGeAlD
Bosutinib—Infection—Epirubicin—ovarian cancer	6.34e-05	0.000536	CcSEcCtD
Bosutinib—Cough—Doxorubicin—ovarian cancer	6.31e-05	0.000534	CcSEcCtD
Bosutinib—Nervous system disorder—Epirubicin—ovarian cancer	6.25e-05	0.000529	CcSEcCtD
Bosutinib—Dizziness—Docetaxel—ovarian cancer	6.25e-05	0.000529	CcSEcCtD
Bosutinib—Thrombocytopenia—Epirubicin—ovarian cancer	6.24e-05	0.000528	CcSEcCtD
Bosutinib—Skin disorder—Epirubicin—ovarian cancer	6.19e-05	0.000524	CcSEcCtD
Bosutinib—Arthralgia—Doxorubicin—ovarian cancer	6.16e-05	0.000521	CcSEcCtD
Bosutinib—Chest pain—Doxorubicin—ovarian cancer	6.16e-05	0.000521	CcSEcCtD
Bosutinib—Myalgia—Doxorubicin—ovarian cancer	6.16e-05	0.000521	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	6.11e-05	0.000517	CcSEcCtD
Bosutinib—Discomfort—Doxorubicin—ovarian cancer	6.08e-05	0.000515	CcSEcCtD
Bosutinib—Vomiting—Docetaxel—ovarian cancer	6.01e-05	0.000509	CcSEcCtD
Bosutinib—Rash—Docetaxel—ovarian cancer	5.96e-05	0.000505	CcSEcCtD
Bosutinib—MAP2K5—lymph node—ovarian cancer	5.96e-05	0.000405	CbGeAlD
Bosutinib—Dermatitis—Docetaxel—ovarian cancer	5.96e-05	0.000504	CcSEcCtD
Bosutinib—Headache—Docetaxel—ovarian cancer	5.92e-05	0.000501	CcSEcCtD
Bosutinib—Anaphylactic shock—Doxorubicin—ovarian cancer	5.9e-05	0.000499	CcSEcCtD
Bosutinib—Oedema—Doxorubicin—ovarian cancer	5.9e-05	0.000499	CcSEcCtD
Bosutinib—Infection—Doxorubicin—ovarian cancer	5.86e-05	0.000496	CcSEcCtD
Bosutinib—CSF1R—lymph node—ovarian cancer	5.81e-05	0.000395	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Epirubicin—ovarian cancer	5.81e-05	0.000492	CcSEcCtD
Bosutinib—Nervous system disorder—Doxorubicin—ovarian cancer	5.79e-05	0.00049	CcSEcCtD
Bosutinib—Thrombocytopenia—Doxorubicin—ovarian cancer	5.78e-05	0.000489	CcSEcCtD
Bosutinib—Skin disorder—Doxorubicin—ovarian cancer	5.73e-05	0.000485	CcSEcCtD
Bosutinib—Dyspnoea—Epirubicin—ovarian cancer	5.69e-05	0.000481	CcSEcCtD
Bosutinib—Nausea—Docetaxel—ovarian cancer	5.62e-05	0.000475	CcSEcCtD
Bosutinib—Decreased appetite—Epirubicin—ovarian cancer	5.54e-05	0.000469	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Epirubicin—ovarian cancer	5.51e-05	0.000466	CcSEcCtD
Bosutinib—Fatigue—Epirubicin—ovarian cancer	5.5e-05	0.000465	CcSEcCtD
Bosutinib—Pain—Epirubicin—ovarian cancer	5.45e-05	0.000462	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	5.38e-05	0.000455	CcSEcCtD
Bosutinib—CHEK2—Vinblastine—Vinorelbine—ovarian cancer	5.31e-05	0.0116	CbGdCrCtD
Bosutinib—Dyspnoea—Doxorubicin—ovarian cancer	5.26e-05	0.000445	CcSEcCtD
Bosutinib—Feeling abnormal—Epirubicin—ovarian cancer	5.26e-05	0.000445	CcSEcCtD
Bosutinib—Gastrointestinal pain—Epirubicin—ovarian cancer	5.21e-05	0.000441	CcSEcCtD
Bosutinib—PDGFRB—lymph node—ovarian cancer	5.16e-05	0.000351	CbGeAlD
Bosutinib—Decreased appetite—Doxorubicin—ovarian cancer	5.13e-05	0.000434	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	5.09e-05	0.000431	CcSEcCtD
Bosutinib—Fatigue—Doxorubicin—ovarian cancer	5.09e-05	0.000431	CcSEcCtD
Bosutinib—Urticaria—Epirubicin—ovarian cancer	5.07e-05	0.000429	CcSEcCtD
Bosutinib—Pain—Doxorubicin—ovarian cancer	5.05e-05	0.000427	CcSEcCtD
Bosutinib—Body temperature increased—Epirubicin—ovarian cancer	5.04e-05	0.000427	CcSEcCtD
Bosutinib—Abdominal pain—Epirubicin—ovarian cancer	5.04e-05	0.000427	CcSEcCtD
Bosutinib—Feeling abnormal—Doxorubicin—ovarian cancer	4.86e-05	0.000412	CcSEcCtD
Bosutinib—Gastrointestinal pain—Doxorubicin—ovarian cancer	4.82e-05	0.000408	CcSEcCtD
Bosutinib—Urticaria—Doxorubicin—ovarian cancer	4.69e-05	0.000397	CcSEcCtD
Bosutinib—Body temperature increased—Doxorubicin—ovarian cancer	4.66e-05	0.000395	CcSEcCtD
Bosutinib—Abdominal pain—Doxorubicin—ovarian cancer	4.66e-05	0.000395	CcSEcCtD
Bosutinib—ABL1—lymph node—ovarian cancer	4.59e-05	0.000313	CbGeAlD
Bosutinib—Asthenia—Epirubicin—ovarian cancer	4.58e-05	0.000387	CcSEcCtD
Bosutinib—Pruritus—Epirubicin—ovarian cancer	4.51e-05	0.000382	CcSEcCtD
Bosutinib—CSK—Doxorubicin—Epirubicin—ovarian cancer	4.4e-05	0.00964	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Epirubicin—ovarian cancer	4.4e-05	0.00964	CbGdCrCtD
Bosutinib—Diarrhoea—Epirubicin—ovarian cancer	4.36e-05	0.000369	CcSEcCtD
Bosutinib—Asthenia—Doxorubicin—ovarian cancer	4.23e-05	0.000358	CcSEcCtD
Bosutinib—Dizziness—Epirubicin—ovarian cancer	4.22e-05	0.000357	CcSEcCtD
Bosutinib—ABCB1—myometrium—ovarian cancer	4.19e-05	0.000285	CbGeAlD
Bosutinib—Pruritus—Doxorubicin—ovarian cancer	4.17e-05	0.000353	CcSEcCtD
Bosutinib—CSK—Epirubicin—Doxorubicin—ovarian cancer	4.07e-05	0.00892	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Doxorubicin—ovarian cancer	4.07e-05	0.00892	CbGdCrCtD
Bosutinib—Vomiting—Epirubicin—ovarian cancer	4.05e-05	0.000343	CcSEcCtD
Bosutinib—Diarrhoea—Doxorubicin—ovarian cancer	4.04e-05	0.000342	CcSEcCtD
Bosutinib—ABCB1—embryo—ovarian cancer	4.03e-05	0.000274	CbGeAlD
Bosutinib—Rash—Epirubicin—ovarian cancer	4.02e-05	0.00034	CcSEcCtD
Bosutinib—Dermatitis—Epirubicin—ovarian cancer	4.02e-05	0.00034	CcSEcCtD
Bosutinib—Headache—Epirubicin—ovarian cancer	3.99e-05	0.000338	CcSEcCtD
Bosutinib—Dizziness—Doxorubicin—ovarian cancer	3.9e-05	0.00033	CcSEcCtD
Bosutinib—Nausea—Epirubicin—ovarian cancer	3.79e-05	0.000321	CcSEcCtD
Bosutinib—Vomiting—Doxorubicin—ovarian cancer	3.75e-05	0.000318	CcSEcCtD
Bosutinib—Rash—Doxorubicin—ovarian cancer	3.72e-05	0.000315	CcSEcCtD
Bosutinib—Dermatitis—Doxorubicin—ovarian cancer	3.72e-05	0.000315	CcSEcCtD
Bosutinib—Headache—Doxorubicin—ovarian cancer	3.7e-05	0.000313	CcSEcCtD
Bosutinib—Nausea—Doxorubicin—ovarian cancer	3.5e-05	0.000297	CcSEcCtD
Bosutinib—CYP3A4—female reproductive system—ovarian cancer	3.45e-05	0.000235	CbGeAlD
Bosutinib—ABCB1—epithelium—ovarian cancer	3.29e-05	0.000224	CbGeAlD
Bosutinib—ABCB1—uterine cervix—ovarian cancer	3.26e-05	0.000222	CbGeAlD
Bosutinib—CHEK2—Doxorubicin—Epirubicin—ovarian cancer	3.22e-05	0.00705	CbGdCrCtD
Bosutinib—ABCB1—decidua—ovarian cancer	3.11e-05	0.000211	CbGeAlD
Bosutinib—ABL1—Daunorubicin—Epirubicin—ovarian cancer	3.07e-05	0.00673	CbGdCrCtD
Bosutinib—ABL1—Doxorubicin—Epirubicin—ovarian cancer	3.07e-05	0.00673	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Epirubicin—ovarian cancer	3.07e-05	0.00673	CbGdCrCtD
Bosutinib—CHEK2—Epirubicin—Doxorubicin—ovarian cancer	2.98e-05	0.00653	CbGdCrCtD
Bosutinib—ABCB1—endometrium—ovarian cancer	2.95e-05	0.000201	CbGeAlD
Bosutinib—ABL1—Daunorubicin—Doxorubicin—ovarian cancer	2.84e-05	0.00623	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Doxorubicin—ovarian cancer	2.84e-05	0.00623	CbGdCrCtD
Bosutinib—ABL1—Epirubicin—Doxorubicin—ovarian cancer	2.84e-05	0.00623	CbGdCrCtD
Bosutinib—ABCB1—gonad—ovarian cancer	2.73e-05	0.000186	CbGeAlD
Bosutinib—ABCB1—uterus—ovarian cancer	2.72e-05	0.000185	CbGeAlD
Bosutinib—ABCB1—female reproductive system—ovarian cancer	2.44e-05	0.000166	CbGeAlD
Bosutinib—ABCB1—bone marrow—ovarian cancer	2.31e-05	0.000157	CbGeAlD
Bosutinib—ABCB1—female gonad—ovarian cancer	2.22e-05	0.000151	CbGeAlD
Bosutinib—ABCB1—vagina—ovarian cancer	2.21e-05	0.00015	CbGeAlD
Bosutinib—ABCB1—testis—ovarian cancer	1.97e-05	0.000134	CbGeAlD
Bosutinib—ABCB1—lymph node—ovarian cancer	1.43e-05	9.72e-05	CbGeAlD
Bosutinib—MAP2K2—Disease—HRAS—ovarian cancer	5.7e-07	2.72e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MAPK1—ovarian cancer	5.69e-07	2.71e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EGFR—ovarian cancer	5.69e-07	2.71e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—KRAS—ovarian cancer	5.69e-07	2.71e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MYC—ovarian cancer	5.69e-07	2.71e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL6—ovarian cancer	5.65e-07	2.69e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CD—ovarian cancer	5.63e-07	2.68e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL6—ovarian cancer	5.62e-07	2.68e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—ERBB2—ovarian cancer	5.62e-07	2.68e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—PIK3CA—ovarian cancer	5.61e-07	2.67e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—MAPK3—ovarian cancer	5.61e-07	2.67e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—AKT1—ovarian cancer	5.59e-07	2.66e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL6—ovarian cancer	5.58e-07	2.66e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—HRAS—ovarian cancer	5.57e-07	2.65e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MAPK1—ovarian cancer	5.56e-07	2.65e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EGFR—ovarian cancer	5.56e-07	2.65e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—ovarian cancer	5.56e-07	2.65e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CB—ovarian cancer	5.55e-07	2.64e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MTOR—ovarian cancer	5.55e-07	2.64e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AKT1—ovarian cancer	5.54e-07	2.64e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—ovarian cancer	5.53e-07	2.64e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PIK3CA—ovarian cancer	5.53e-07	2.64e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCL8—ovarian cancer	5.53e-07	2.64e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—ovarian cancer	5.53e-07	2.63e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HRAS—ovarian cancer	5.5e-07	2.62e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—STAT3—ovarian cancer	5.47e-07	2.61e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NRAS—ovarian cancer	5.46e-07	2.6e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—ovarian cancer	5.46e-07	2.6e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AKT1—ovarian cancer	5.46e-07	2.6e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—KRAS—ovarian cancer	5.45e-07	2.6e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—ovarian cancer	5.43e-07	2.59e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PIK3CA—ovarian cancer	5.43e-07	2.59e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—STAT3—ovarian cancer	5.42e-07	2.58e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—NRAS—ovarian cancer	5.41e-07	2.58e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1B—ovarian cancer	5.4e-07	2.57e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—ovarian cancer	5.39e-07	2.57e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—ovarian cancer	5.38e-07	2.56e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—HRAS—ovarian cancer	5.37e-07	2.56e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—ovarian cancer	5.35e-07	2.55e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—ovarian cancer	5.34e-07	2.55e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—ovarian cancer	5.34e-07	2.55e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—STAT3—ovarian cancer	5.34e-07	2.55e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HRAS—ovarian cancer	5.34e-07	2.54e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—MAPK1—ovarian cancer	5.34e-07	2.54e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—ovarian cancer	5.33e-07	2.54e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL8—ovarian cancer	5.33e-07	2.54e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NRAS—ovarian cancer	5.33e-07	2.54e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—ovarian cancer	5.33e-07	2.54e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—ovarian cancer	5.32e-07	2.54e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CASP3—ovarian cancer	5.29e-07	2.52e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL2—ovarian cancer	5.29e-07	2.52e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—ovarian cancer	5.28e-07	2.52e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—ovarian cancer	5.26e-07	2.51e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—ovarian cancer	5.26e-07	2.5e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PIK3CA—ovarian cancer	5.25e-07	2.5e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—PIK3CA—ovarian cancer	5.23e-07	2.49e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—STAT3—ovarian cancer	5.23e-07	2.49e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MAPK3—ovarian cancer	5.23e-07	2.49e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NRAS—ovarian cancer	5.22e-07	2.49e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—ovarian cancer	5.21e-07	2.48e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1B—ovarian cancer	5.21e-07	2.48e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—ovarian cancer	5.2e-07	2.48e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HRAS—ovarian cancer	5.19e-07	2.47e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—ovarian cancer	5.19e-07	2.47e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MAPK3—ovarian cancer	5.18e-07	2.47e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—ovarian cancer	5.17e-07	2.46e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—FASN—ovarian cancer	5.17e-07	2.46e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCND1—ovarian cancer	5.15e-07	2.46e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—STAT3—ovarian cancer	5.15e-07	2.45e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—ovarian cancer	5.15e-07	2.45e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NRAS—ovarian cancer	5.14e-07	2.45e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—ovarian cancer	5.14e-07	2.45e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—ovarian cancer	5.13e-07	2.45e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—STAT3—ovarian cancer	5.12e-07	2.44e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HRAS—ovarian cancer	5.12e-07	2.44e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NRAS—ovarian cancer	5.11e-07	2.43e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—ovarian cancer	5.11e-07	2.43e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—ovarian cancer	5.1e-07	2.43e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MAPK3—ovarian cancer	5.1e-07	2.43e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CTNNB1—ovarian cancer	5.1e-07	2.43e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CASP3—ovarian cancer	5.1e-07	2.43e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2—ovarian cancer	5.09e-07	2.43e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—ovarian cancer	5.09e-07	2.42e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	5.08e-07	2.42e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—ovarian cancer	5.08e-07	2.42e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—ovarian cancer	5.04e-07	2.4e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—ovarian cancer	5.04e-07	2.4e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—ovarian cancer	5.04e-07	2.4e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HRAS—ovarian cancer	5.02e-07	2.39e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—PIK3CA—ovarian cancer	5.01e-07	2.39e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—ovarian cancer	5e-07	2.38e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MAPK3—ovarian cancer	5e-07	2.38e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CAV1—ovarian cancer	4.98e-07	2.37e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ERBB2—ovarian cancer	4.98e-07	2.37e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MAPK1—ovarian cancer	4.98e-07	2.37e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—ovarian cancer	4.98e-07	2.37e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PTEN—ovarian cancer	4.97e-07	2.37e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—ovarian cancer	4.97e-07	2.37e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCND1—ovarian cancer	4.97e-07	2.37e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—ovarian cancer	4.96e-07	2.36e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PIK3CA—ovarian cancer	4.94e-07	2.35e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MAPK1—ovarian cancer	4.93e-07	2.35e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—ovarian cancer	4.93e-07	2.35e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MAPK3—ovarian cancer	4.92e-07	2.34e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CTNNB1—ovarian cancer	4.92e-07	2.34e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—ovarian cancer	4.92e-07	2.34e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MTOR—ovarian cancer	4.91e-07	2.34e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CB—ovarian cancer	4.91e-07	2.34e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	4.91e-07	2.34e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—ovarian cancer	4.9e-07	2.33e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MAPK3—ovarian cancer	4.89e-07	2.33e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—ovarian cancer	4.86e-07	2.32e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MAPK1—ovarian cancer	4.86e-07	2.31e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—ovarian cancer	4.85e-07	2.31e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HRAS—ovarian cancer	4.85e-07	2.31e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—ovarian cancer	4.85e-07	2.31e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—HRAS—ovarian cancer	4.84e-07	2.31e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PIK3CA—ovarian cancer	4.83e-07	2.3e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—ovarian cancer	4.82e-07	2.3e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—ovarian cancer	4.81e-07	2.29e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PTEN—ovarian cancer	4.79e-07	2.28e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—ovarian cancer	4.78e-07	2.28e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—ovarian cancer	4.78e-07	2.28e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—ovarian cancer	4.76e-07	2.27e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MAPK1—ovarian cancer	4.75e-07	2.27e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—ovarian cancer	4.75e-07	2.26e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—ovarian cancer	4.74e-07	2.26e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL8—ovarian cancer	4.72e-07	2.25e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—ovarian cancer	4.71e-07	2.25e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	4.71e-07	2.24e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—ovarian cancer	4.7e-07	2.24e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MAPK1—ovarian cancer	4.68e-07	2.23e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—ovarian cancer	4.68e-07	2.23e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MAPK1—ovarian cancer	4.66e-07	2.22e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—ovarian cancer	4.65e-07	2.22e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—ovarian cancer	4.65e-07	2.22e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—ovarian cancer	4.65e-07	2.21e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—HRAS—ovarian cancer	4.64e-07	2.21e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—ovarian cancer	4.63e-07	2.21e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—PIK3CA—ovarian cancer	4.63e-07	2.21e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1B—ovarian cancer	4.61e-07	2.2e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—ovarian cancer	4.59e-07	2.19e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—ovarian cancer	4.58e-07	2.18e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HRAS—ovarian cancer	4.57e-07	2.18e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CG—ovarian cancer	4.53e-07	2.16e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—ovarian cancer	4.52e-07	2.15e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CASP3—ovarian cancer	4.52e-07	2.15e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2—ovarian cancer	4.51e-07	2.15e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—ovarian cancer	4.49e-07	2.14e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—ovarian cancer	4.49e-07	2.14e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—HRAS—ovarian cancer	4.47e-07	2.13e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—STAT3—ovarian cancer	4.45e-07	2.12e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NRAS—ovarian cancer	4.44e-07	2.11e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—ovarian cancer	4.44e-07	2.11e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—ovarian cancer	4.43e-07	2.11e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—ovarian cancer	4.42e-07	2.11e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—ovarian cancer	4.4e-07	2.09e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCND1—ovarian cancer	4.4e-07	2.09e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—ovarian cancer	4.38e-07	2.08e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CTNNB1—ovarian cancer	4.35e-07	2.07e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—ovarian cancer	4.33e-07	2.06e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PIK3CA—ovarian cancer	4.32e-07	2.06e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—ovarian cancer	4.29e-07	2.04e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—STAT3—ovarian cancer	4.29e-07	2.04e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—HRAS—ovarian cancer	4.28e-07	2.04e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NRAS—ovarian cancer	4.28e-07	2.04e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—ovarian cancer	4.28e-07	2.04e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PIK3CA—ovarian cancer	4.27e-07	2.04e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—ovarian cancer	4.27e-07	2.04e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—ovarian cancer	4.27e-07	2.03e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK3—ovarian cancer	4.25e-07	2.02e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTEN—ovarian cancer	4.24e-07	2.02e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PIK3CA—ovarian cancer	4.21e-07	2.01e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—ovarian cancer	4.18e-07	1.99e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	4.17e-07	1.99e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—ovarian cancer	4.13e-07	1.97e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PIK3CA—ovarian cancer	4.13e-07	1.97e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—ovarian cancer	4.1e-07	1.95e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK3—ovarian cancer	4.1e-07	1.95e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—ovarian cancer	4.09e-07	1.95e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—ovarian cancer	4.08e-07	1.94e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PIK3CA—ovarian cancer	4.06e-07	1.94e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK1—ovarian cancer	4.04e-07	1.93e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PIK3CA—ovarian cancer	4.04e-07	1.92e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—ovarian cancer	4.04e-07	1.92e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRAS—ovarian cancer	3.99e-07	1.9e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—ovarian cancer	3.99e-07	1.9e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CD—ovarian cancer	3.99e-07	1.9e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—ovarian cancer	3.98e-07	1.9e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—HRAS—ovarian cancer	3.96e-07	1.88e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—ovarian cancer	3.94e-07	1.88e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—ovarian cancer	3.93e-07	1.87e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—ovarian cancer	3.91e-07	1.86e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRAS—ovarian cancer	3.9e-07	1.86e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK1—ovarian cancer	3.9e-07	1.86e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—ovarian cancer	3.9e-07	1.86e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ABCB1—ovarian cancer	3.88e-07	1.85e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—ovarian cancer	3.83e-07	1.83e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—ovarian cancer	3.82e-07	1.82e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—ovarian cancer	3.82e-07	1.82e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRAS—ovarian cancer	3.82e-07	1.82e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TYMS—ovarian cancer	3.81e-07	1.81e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—STAT3—ovarian cancer	3.79e-07	1.81e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NRAS—ovarian cancer	3.79e-07	1.8e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—ovarian cancer	3.79e-07	1.8e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—ovarian cancer	3.78e-07	1.8e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRAS—ovarian cancer	3.76e-07	1.79e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRAS—ovarian cancer	3.74e-07	1.78e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—ovarian cancer	3.73e-07	1.78e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—ovarian cancer	3.68e-07	1.75e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—ovarian cancer	3.65e-07	1.74e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK3—ovarian cancer	3.63e-07	1.73e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—ovarian cancer	3.6e-07	1.71e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—ovarian cancer	3.58e-07	1.7e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—ovarian cancer	3.53e-07	1.68e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—ovarian cancer	3.53e-07	1.68e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CA—ovarian cancer	3.51e-07	1.67e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—ovarian cancer	3.49e-07	1.66e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CB—ovarian cancer	3.47e-07	1.66e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK1—ovarian cancer	3.45e-07	1.64e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—ovarian cancer	3.45e-07	1.64e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—ovarian cancer	3.44e-07	1.64e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—ovarian cancer	3.39e-07	1.62e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CA—ovarian cancer	3.38e-07	1.61e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—ovarian cancer	3.37e-07	1.61e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—ovarian cancer	3.32e-07	1.58e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—ovarian cancer	3.3e-07	1.57e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—ovarian cancer	3.27e-07	1.56e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—ovarian cancer	3.26e-07	1.55e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRAS—ovarian cancer	3.25e-07	1.55e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRAS—ovarian cancer	3.13e-07	1.49e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—ovarian cancer	3.11e-07	1.48e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CAV1—ovarian cancer	3.07e-07	1.46e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTEN—ovarian cancer	3e-07	1.43e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—ovarian cancer	2.99e-07	1.43e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CA—ovarian cancer	2.99e-07	1.43e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—ovarian cancer	2.9e-07	1.38e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—ovarian cancer	2.87e-07	1.37e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.79e-07	1.33e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRAS—ovarian cancer	2.77e-07	1.32e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—ovarian cancer	2.76e-07	1.32e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—ovarian cancer	2.65e-07	1.26e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.46e-07	1.17e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—ovarian cancer	2.45e-07	1.17e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.14e-07	1.02e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.12e-07	1.01e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTEN—ovarian cancer	1.85e-07	8.81e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—ovarian cancer	1.73e-07	8.24e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.3e-07	6.22e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—ovarian cancer	1.07e-07	5.08e-07	CbGpPWpGaD
